Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

NCT02432703
completedphase_2

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

NCT02498392
completedphase_1

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

NCT03564379
completedphase_2

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

NCT03664232
completedphase_1

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

NCT02169973
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02432703Phase 2

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Completed
NCT02498392Phase 2

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

Completed
NCT03564379Phase 1

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

Completed
NCT03664232Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

Completed
NCT02169973Phase 1

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Completed
NCT02065739Phase 1

A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6